Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
FAQs
Advertising
Report Store
UsernamePublicRestriction
Tags:
Coronavirus COVID-19 Approvals Europe

Coronavirus Notebook: UK OKs Moderna Vaccine & Use Of Tocilizumab/Sarilumab In Hospitalized Patients

  • News

Executive Summary

The EMA explains how to get six doses from a vial of the Pfizer/BioNTech vaccine, while the UK seems isolated in its decision to give the second dose of the vaccine 12 weeks after the first.

You may also be interested in...



EU Parliamentarians To Get Sight Of First COVID-19 Vaccine Contract

The advance purchase agreement signed by CureVac and the European Commission for the supply of a coronavirus vaccine is being made available for scrutiny, but only by MEPs and in the confines of the European Parliament.

EU Approval Of Oxford/AstraZeneca COVID-19 Vaccine Expected By End Of January

AstraZeneca is expected to apply for the EU approval of its COVID-19 vaccine next week. The vaccine was developed in partnership with the University of Oxford. 

Moderna Wins EU Approval For COVID-19 Vaccine

The first deliveries of Moderna’s COVID-19 vaccine to European countries are expected to begin next week.

Table

View full table

Topics

Related Companies

Tags:
Coronavirus COVID-19 Approvals Europe
UsernamePublicRestriction

Register

ID1125791

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By